Literature DB >> 28395815

Erratum to "Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update": Canadian Journal of Diabetes 2016;40:484-6.

.   

Abstract

Entities:  

Year:  2017        PMID： 28395815     DOI： 10.1016/j.jcjd.2017.01.006

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN： 1499-2671            Impact factor:   4.190


× No keyword cloud information.
  4 in total

Review 1.  Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.

Authors:  Elif A Oral
Journal:  Drugs Context       Date:  2016-09-02

Review 2.  Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

Authors:  John E Anderson; Eugene E Wright; Charles F Shaefer
Journal:  Diabetes Ther       Date:  2016-11-11       Impact factor: 2.945

3.  Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.

Authors:  Solomon Nuhoho; Jatin Gupta; Brian Bekker Hansen; Mary Fletcher-Louis; Tam Dang-Tan; Abby Paine
Journal:  Diabetes Ther       Date:  2019-10-10       Impact factor: 2.945

Review 4.  Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice.

Authors:  David H Fitchett
Journal:  Eur Endocrinol       Date:  2018-09-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.